


Remarks:

1. Claim 1 is amended to require that the polynucleotide of section (d) has at least 95% identity and encodes a leukotriene receptor. Support for this amendment is found in the specification, for example, at page 15, lines 15-19, and at pages 71-74. Claims 4-6 and 24-26 are amended for clarification. Claim 6 is amended to put the claim in independent form. Claim 33 is amended for correction of dependency. No new matter is added by amendment.
2. Claims 1-6 and 22-33 are pending.
3. Claim 2 stands rejected, under 35 U.S.C. § 112, first paragraph. This claim is cancelled herein and the rejection is moot.
4. Claims 1-6, 23, and 27-33 stand rejected, under 35 U.S.C. § 112, second paragraph, as indefinite regarding the recited hybridization language. In view of the current amendment to claims 1 and 6, the only currently pending independent claims relevant to this rejection, deleting hybridization language, Applicants request reconsideration and withdrawal of this rejection.
5. Claims 31-33 are objected to for improper multiple dependent form. Claims 31 and 32 are cancelled herein and amended claim 33 is now in proper form.
6. Claim 6 is objected to for improper dependent form. This claim is redrafted herein as an independent claim.
7. Claim 4 is rejected, under 35 U.S.C. § 112, first paragraph. In view of the current amendment to the claim, Applicants request reconsideration and withdrawal of this rejection.
8. Claim 5 is rejected, 35 U.S.C. § 112, second paragraph, as indefinite. In view of the current amendment deleting reference to “a polypeptide fragment,” Applicants request reconsideration and withdrawal of this rejection.
9. Claims 23 and 28 stand rejected, under 35 U.S.C. § 101 and 35 U.S.C. § 112, second paragraph. These claims are cancelled herein.
10. Claims 29 and 30 stand rejected, under 35 U.S.C. § 112, second paragraph. These claims are cancelled herein.

Patent Application
Attorney Docket No. PCS10914ADAM

Date: June 11, 2003

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Deborah A. Martin", is written over a horizontal line.

Deborah A. Martin
Attorney for Applicant(s)
Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-1821

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Twice Amended) An isolated and/or purified polynucleotide comprising ~~one or more of:~~
 - (a) a polynucleotide encoding a polypeptide comprising SEQ ID NO: 2 or SEQ ID NO: 6;
 - (b) a polynucleotide comprising a nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 5;
 - (c) ~~a polynucleotide, wherein the complement of said polynucleotide hybridizes to the full length coding sequence of (a) or (b) under moderate stringency;~~
 - (d) ~~—a polynucleotide comprising the cDNA of deposit NCIMB 41074; and~~
 - (e) ~~—a complement to the polynucleotide of any one of (a), (b), (c), or (d).~~

or

(d) a polynucleotide comprising a nucleotide sequence that has at least 95% identity to the polynucleotide of (a), (b), or (c), and which encodes a leukotriene receptor.
3. A vector comprising the polynucleotide of claim 1.
4. (Twice Amended) A host cell transformed or transfected with the ~~vector of claim 3~~ polynucleotide of claim 1, wherein said host cell expresses ~~a polypeptide of SEQ ID NO: 2 or SEQ ID NO: 6~~ said polynucleotide under conditions sufficient for expression of the polypeptide.
5. (Twice Amended) A process for producing a polypeptide ~~fragment thereof~~ encoded by the polynucleotide of claim 1 comprising culturing the transformed/transfected host cell of claim 4 under conditions sufficient for ~~the expression of said polypeptide fragment.~~
6. (Twice Amended) A membrane preparation of a cell transformed or transfected with
 - (a) a polynucleotide encoding a polypeptide comprising SEQ ID NO: 2 or SEQ ID NO: 6;
 - (b) a polynucleotide comprising a nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 5;

- (c) a polynucleotide comprising the cDNA of deposit NCIMB 41074; or
- (d) a polynucleotide comprising a nucleotide sequence that has at least 95% identity to the polynucleotide of (a), (b), or (c), and which encodes a leukotriene receptor of claim 4 or 5.
22. A microorganism as deposited under the accession number NCIMB 41074 at the National Collections of Industrial and Marine Bacteria Ltd.
24. (Amended) An isolated and/or purified polynucleotide ~~comprising: a polynucleotide~~ encoding a polypeptide comprising SEQ ID NO: 2 or SEQ ID NO: 6.
25. (Amended) An isolated and/or purified polynucleotide ~~comprising: a polynucleotide comprising a nucleotide sequence~~ comprising SEQ ID NO: 1 or SEQ ID NO: 5.
26. (Amended) An isolated and/or purified polynucleotide ~~comprising: a polynucleotide~~ comprising the cDNA of deposit NCIMB 41074.
33. (Amended) A vector comprising the polynucleotide of any one of claims 24-26 ~~to 27 or 29 to 30.~~